the U.s. patent office has granted the Brighters primary patents in the united states, which includes the Actiste and its unique ability to integrate all the functions in the patient's aktivitetskedja in one and the same entity, that is to say, to measure and analyze a biomarker (t.ex.
blood glucose), and inject the medicine (t.ex.
" the Approval of our primary means to an important piece of the puzzle in our global expansion plan has now fallen in place.
the Potential in the US is huge given the large number of people with diabetes there and on the entire american continent and, even if we have chosen to initially launch the solution in Sweden, Indonesia and Thailand are the united states, and large parts of south America, the key markets which we expect to expand to in the future, " says Truls Sjöstedt, Brighters ceo and founder.
the Grant applies to the Brighters primary patents which protect the company's unique integration of all the functionalities, that is to say, measure and analyze a biomarker and inject the medicine, in one and the same instrument.
Actiste is the company's first application based on this which means a mobiluppkopplat full-integrated tool for diabetics containing thyroid blood tests, blodsockeranalys and insulininjektion.